Understanding velocardiofacial syndrome: How recent discoveries can help you improve your patient outcomes

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 20, Issue 6, 2012, Pages 502-506

  Chinnadurai, Sivakumar ^a   Goudy, Steven ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

22q11.2; Digeorge; T Box transcription factor 1; velocardiofacial; velopharyngeal insufficiency

Indexed keywords

CALCIUM; T BOX TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; AUDITORY TUBE DYSFUNCTION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CHRONIC OTITIS MEDIA; CLEFT PALATE; COGNITIVE DEFECT; CONDUCTION DEAFNESS; CRANIOFACIAL DEVELOPMENT; DEPRESSION; ELECTROLYTE DISTURBANCE; EMBRYO DEVELOPMENT; ENDODERM; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GENETIC ANALYSIS; HEART DISEASE; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; MOLECULAR GENETICS; NEUROPSYCHIATRY; NONHUMAN; PALATOPHARYNGEAL INCOMPETENCE; PARATHYROID FUNCTION; PARATHYROID TRANSPLANTATION; PERCEPTION DEAFNESS; PHOBIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL STATUS; SPEECH REHABILITATION; SPEECH THERAPY; THYMUS TRANSPLANTATION; VELOCARDIOFACIAL SYNDROME;

ANIMALS; BRANCHIAL REGION; CALCIUM; DIGEORGE SYNDROME; GENETIC THERAPY; HOMEOSTASIS; HUMANS; PARATHYROID GLANDS; PHENOTYPE; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES; THYMUS GLAND; TRETINOIN;

EID: 84870244249     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0b013e328359b476     Document Type: Review

References (24)

1. DiGeorge A. Congenital absence of the thymus and its immunologic consequences: concurrence with congenital hypoparathyroidism. March of Dimes-Birth Defect Foundation 1968; (IV):116-121.
2. Shprintzen RJ, Goldberg RB, Lewin ML, et al. A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardiofacial syndrome. Cleft Palate J 1978; 15:56-62. (Pubitemid 8271057)
3. Markert ML, Devlin BH, Alexieff MJ, et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 2007; 109:4539-4547. (Pubitemid 46743425)
4. Grevellec A, Tucker AS. The pharyngeal pouches and clefts: development, evolution, structure and derivatives. Semin Cell Dev Biol 2010; 21:325-332.
5. Goudy S, Law A, Sanchez G, et al. Tbx1 is necessary for palatal elongation and elevation. Mech Dev 2010; 127:292-300.
6. Mirilas P. Lateral congenital anomalies of the pharyngeal apparatus: part I. Normal developmental anatomy (embryogenesis) for the surgeon. Am Surg 2011; 77:1230-1242.
7. Funke B, Epstein JA, Kochilas LK, et al. Mice overexpressing genes from the 22q11 region deleted in velo-cardio-facial syndrome/DiGeorge syndrome have middle and inner ear defects. Hum Mol Genet 2001; 10:2549-2556. (Pubitemid 33095005)
8. Mesbah K, Rana MS, Francou A, et al. Identification of a Tbx1/Tbx2/Tbx3 genetic pathway governing pharyngeal and arterial pole morphogenesis. Hum Mol Genet 2012; 21:1217-1229.
9. Parisot P, Mesbah K, Theveniau-Ruissy M, Kelly RG. Tbx1, subpulmonary myocardium and conotruncal congenital heart defects. Birth Defects Res A Clin Mol Teratol 2011; 91:477-484.
10. Ryckebusch L, Bertrand N, Mesbah K, et al. Decreased levels of embryonic retinoic acid synthesis accelerate recovery from arterial growth delay in a mouse model of DiGeorge syndrome. Circ Res 2010; 106:686-694.
11. Stalmans I, Lambrechts D, De Smet F, et al. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med 2003; 9:173-182.
12. Theveniau-Ruissy M, Dandonneau M, Mesbah K, et al. The del22q11.2 candidate gene Tbx1 controls regional outflow tract identity and coronary artery patterning. Circ Res 2008; 103:142-148.
13. Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008; 9:541-553. (Pubitemid 351861538)
14. Sauce D, Appay V. Altered thymic activity in early life: how does it affect the immune system in young adults? Curr Opin Immunol 2011; 23:543-548.
15. Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol 2010; 135:236-246.
16. Chinn IK, Markert ML. Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly. J Allerg Clin Immunol 2011; 127:1351-1355.
17. Chinn IK, Olson JA, Skinner MA, et al. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allerg Clin Immunol 2010; 126:814-820; e818.
18. Gennery AR. Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci: CMLS 2012; 69:17-27.
19. Momma K. Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome. Am J Cardiol 2010; 105:1617-1624.
20. Looman WS, Thurmes AK, O'Conner-Von SK. Quality of life among children with velocardiofacial syndrome. Cleft Palate Craniofac J 2010; 47:273-283.
21. Antshel KM, Fremont W, Kates WR. The neurocognitive phenotype in velocardio-facial syndrome: a developmental perspective. Dev Disabil Res Rev 2008; 14:43-51. (Pubitemid 351716522)
22. Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. Late-onset psychosis in the velo-cardio-facial syndrome.AmJMedGenet 1992; 42:141-142.
23. Kates WR, Krauss BR, Abdulsabur N, et al. The neural correlates of nonspatial working memory in velocardiofacial syndrome (22q11.2 deletion syndrome). Neuropsychologia 2007; 45:2863-2873. (Pubitemid 47176594)
24. Kunwar A, Ramanathan S, Nelson J, et al. Cortical gyrification in velo-cardiofacial (22q11.2 deletion) syndrome: a longitudinal study. Schizophr Res 2012; 137:20-25.